Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25035199 | 0.80 | TDP1 (0.51) | DHFR | |
| SCHEMBL30475479 | 0.80 | TDP1 (0.51) | DHFR | |
| SCHEMBL11433418 | 0.80 | HSD17B10 (0.67) | HSD17B10MTNR1AMTNR1BCAPN1 | |
| SCHEMBL25035196 | 0.80 | ALDH1A1 (0.45) | DHFRMTNR1AMTNR1B | |
| SCHEMBL25033927 | 0.78 | TDP1 (0.48) | — | |
| SCHEMBL13964605 | 0.77 | MTNR1A (0.44) | HSD17B10MTNR1AMTNR1BCAPN1 | |
| SCHEMBL25033924 | 0.77 | ALDH1A1 (0.45) | DHFRMTNR1AMTNR1B | |
| SCHEMBL27621740 | 0.76 | HSD17B10 (0.65) | DHFRHSD17B10MTNR1AMTNR1BLTB4R | |
| SCHEMBL25819476 | 0.76 | MAPT (0.44) | — | |
| SCHEMBL10335441 | 0.76 | LMNA (0.53) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | DHFR 3049/4885HSD17B10 2913/4885MTNR1A 3099/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | DHFR 743/4885HSD17B10 3131/4885MTNR1A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.